A Phase 1/2 interventional study of MOR202 in Glomerulonephritis, Membranous and antiPLA2R Positive, sponsored by HI-Bio, A Biogen Company. Completed at 45 sites in 9 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-02-24.
Sponsored by HI-Bio, A Biogen Company (part of Biogen) · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 35 studies in Glomerulonephritis, Membranous with a site in United States — 13 open to participants now, 16 under way, 5 of them phase 3. Glomerulonephritis, Membranous · United States.
Among the 35 studies in Glomerulonephritis, Membranous with a site in United States, this one is the 15th largest by enrollment of the 32 interventional ones that give a count, is the only one that started in 2019, is one of 3 in phase 1/2, and was the 20th registered.
146 studies on the registry are indexed under Glomerulonephritis, Membranous; 60 are open to participants now.
Browse Glomerulonephritis, Membranous studies →13 of the 35 studies in Glomerulonephritis, Membranous with a site in United States are open now. Recruiting first, the newest first:
National Human Genome Research Institute (NHGRI) · Sites in United States
Ages 18–115
Amgen · Sites in United States
Ages 18–79
Pediatric Nephrology Research Consortium · Sites in United States
Ages up to 18
AstraZeneca · Sites in United States, Belgium, China and 6 more countries
Ages 18–75
Vertex Pharmaceuticals Incorporated · Sites in United States, Australia, Brazil and 11 more countries
Ages 18–75
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 41 Glomerulonephritis, Membranous studies recruiting now, 14 (34%) set no upper age limit and 14 (34%) stop at 75 or younger; 8 take children under 18; 2 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
35 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 18 · Phase 3 7 · Phase 4 4
First in 2002; this study’s year is marked. 1 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 31 is below the median of 46 across 105 interventional studies indexed under Glomerulonephritis, Membranous.
Median enrollment 31 across the 32 interventional studies, 1,000 across the 3 observational. Of the 17 that completed or were terminated, 9 (53%) have results posted.
This tab as a report to print or save as PDF → With an account.
17 of 35 have an industry lead sponsor. The 10 most frequent:
This study is registered under HI-Bio, A Biogen Company, one of the names counted as Biogen. Under that name alone:
HI-Bio, A Biogen Company is the lead sponsor of 5 studies on the registry; none are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 2 (40%) have results posted.
Biogen has 4 studies filed under Glomerulonephritis, Membranous — fewer than ten, so there is no comparison to draw.
3 of the studies in Glomerulonephritis, Membranous with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05707377Phase 3BeOne MedicinesA Study to Examine the Efficacy and Safety of Zanubrutinib Given to Adults With Primary Membranous Nephropathy | 2027-10 |
| NCT07157787Alexion Pharmaceuticals, Inc.Study of ALXN1920 in Adult Participants With Primary Membranous Nephropathy (PMN) | 2027-07-02 |
| NCT07096843Climb Bio, Inc.A Phase 2 Study of Budoprutug in Subjects With Primary Membranous Nephropathy | 2027-10 |
Add all 3 to your calendar (.ics) → With an account.
Among the 35 studies in Glomerulonephritis, Membranous with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is an open-label, multicentre study to characterize the safety and efficacy of the human anti-CD38 antibody MOR202 in adult subjects with in Anti-PLA2R Antibody Positive Membranous Nephropathy (newly diagnosed/relapsed/refractory)
After treatment subjects will be observed for up to 1 year.
Study Sponsor, originally HI-Bio, Inc., is now HI-Bio, A Biogen Company.
Key Inclusion Criteria:
Note: France will only enroll patients in Cohort 2.
Key Exclusion Criteria:
Subjects may receive supportive therapies to meet the above criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants with newly diagnosed or relapsed membranous nephropathy received MOR202 as an intravenous infusion over 6 treatment cycles of 28-days each. Dosing occurred weekly in Cycle 1 and every 4 weeks in Cycles 2 to 6.
Drug: MOR202
Participants with membranous nephropathy refractory to immunosuppressive treatment received MOR202 as an intravenous infusion over 6 treatment cycles of 28-days each. Dosing occurred weekly in Cycle 1 and every 4 weeks in Cycles 2 to 6.
Drug: MOR202
Patients received 9 doses of MOR202 as an intravenous infusion over 6 treatment cycles of 28-days each. Dosing occured weekly in Cycle 1 and every 4 weeks in Cycles 2 to 6.
Number of Participants With Adverse Events
An adverse event (AE) was defined as any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. SAEs were defined as death, a life-threatening AE, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, a congenital anomaly or birth defect, or an important medical event that jeopardized participant and required medical intervention to prevent 1 of the outcomes listed in this definition. A summary of other non-serious AEs and all serious AEs, regardless of causality is located in Reported AE section.
Time frame: Week 1 to Week 24
Percentage of Participants With Adverse Events
An AE was defined as any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. SAEs were defined as death, a life-threatening AE, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, a congenital anomaly or birth defect, or an important medical event that jeopardized participant and required medical intervention to prevent 1 of the outcomes listed in this definition. A summary of other non-serious AEs and all serious AEs, regardless of causality is located in Reported AE section.
Time frame: Week 1 to Week 24
Best Immunological Response Rate (BIRR)
The BIRR was defined as the percentage of participants with a best immunological response of stringent immunological complete response (sICR), immunological complete response (ICR), or immunological partial response (IPR) prior to the start of prohibited treatment or progression, based on reduction of serum anti-PLA2R antibody titer.
Time frame: Up to 52 weeks
Number of Participants Tested Positive for Anti-felzartamab Antibodies
Time frame: Baseline; Up to 52 weeks
Percentage of Participants Tested Positive for Anti-felzartamab Antibodies
Time frame: Baseline; Up to 52 weeks
Antibody Titers of Participants Tested Positive for Anti-felzartamab Antibodies
Time frame: Baseline; Up to 52 weeks
Felzartamab Serum Concentrations After Multiple Intravenous Administrations
Time frame: Pre Dose and Post Dose on Cycle 1 Day 1 (C1D1), C1D8, C1D15, C1D22, C2D1, C3D1, C4D1, C5D1, C6D1, End of Treatment (week 24), Follow-up visit (week 38), End of Study (up to 52 weeks)
Number of Participants With AEs During the Follow-up Period
An AE was defined as any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. SAEs were defined as death, a life-threatening AE, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, a congenital anomaly or birth defect, or an important medical event that jeopardized participant and required medical intervention to prevent 1 of the outcomes listed in this definition. A summary of other non-serious AEs and all serious AEs, regardless of causality is located in Reported AE section.
Time frame: Week 25 to Week 52
Percentage of Participants With AEs During the Follow-up Period
An AE was defined as any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. SAEs were defined as death, a life-threatening AE, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, a congenital anomaly or birth defect, or an important medical event that jeopardized participant and required medical intervention to prevent 1 of the outcomes listed in this definition. A summary of other non-serious AEs and all serious AEs, regardless of causality is located in Reported AE section.
Time frame: Week 25 to Week 52
| Milestone | Cohort 1 (Newly Diagnosed or Relapsed Participants) | Cohort 2 (Refractory Participants) |
|---|---|---|
| Started | 18 | 13 |
| Received at least 1 dose of study drug | 18 | 13 |
| Completed | 13 | 10 |
| Not completed | 5 | 3 |
| Withdrew: Physician decision | 3 | 0 |
| Withdrew: Use of prohibited therapy | 2 | 3 |
An adverse event (AE) was defined as any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. SAEs were defined as death, a life-threatening AE, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, a congenital anomaly or birth defect, or an important medical event that jeopardized participant and required medical intervention to prevent 1 of the outcomes listed in this definition. A summary of other non-serious AEs and all serious AEs, regardless of causality is located in Reported AE section.
| Participants | Cohort 1 (Newly Diagnosed or Relapsed Participants) | Cohort 2 (Refractory Participants) |
|---|---|---|
| Number of Participants With Adverse Events | 15 | 12 |
An AE was defined as any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. SAEs were defined as death, a life-threatening AE, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, a congenital anomaly or birth defect, or an important medical event that jeopardized participant and required medical intervention to prevent 1 of the outcomes listed in this definition. A summary of other non-serious AEs and all serious AEs, regardless of causality is located in Reported AE section.
| percentage of participants | Cohort 1 (Newly Diagnosed or Relapsed Participants) | Cohort 2 (Refractory Participants) |
|---|---|---|
| Percentage of Participants With Adverse Events | 83.3 | 92.3 |
The BIRR was defined as the percentage of participants with a best immunological response of stringent immunological complete response (sICR), immunological complete response (ICR), or immunological partial response (IPR) prior to the start of prohibited treatment or progression, based on reduction of serum anti-PLA2R antibody titer.
| percentage of participants | Cohort 1 (Newly Diagnosed or Relapsed Participants) | Cohort 2 (Refractory Participants) |
|---|---|---|
| Best Immunological Response Rate (BIRR) | 83.3 (58.6 to 96.4) | 61.5 (31.6 to 86.1) |
| Participants | Cohort 1 (Newly Diagnosed or Relapsed Participants) | Cohort 2 (Refractory Participants) |
|---|---|---|
| Baseline | 1 | 1 |
| Post First Dose (52 weeks) | 1 | 0 |
| percentage of participants | Cohort 1 (Newly Diagnosed or Relapsed Participants) | Cohort 2 (Refractory Participants) |
|---|---|---|
| Baseline | 6.7 | 7.7 |
| Post First Dose (52 weeks) | 6.7 | 0.0 |
| anti-felzartamab antibody titers | Cohort 1 (Newly Diagnosed or Relapsed Participants) | Cohort 2 (Refractory Participants) |
|---|---|---|
| Baseline | 13.10 ± NA | 11.50 ± NA |
| Post First Dose (52 weeks) | 3.48 ± NA | — |
| nanogram(s)/millilitre (ng/mL) | Cohort 1 (Newly Diagnosed or Relapsed Participants) | Cohort 2 (Refractory Participants) |
|---|---|---|
| Pre-dose C1D1 | 0.0 ± 0.0 | 0.0 ± 0.0 |
| Post-dose C1D1 | 323499.3 ± 98.3 | 301417.5 ± 151.9 |
| Pre-dose C1D8 | 89381.7 ± 97.9 | 129924.9 ± 100.7 |
| Post-dose C1D8 | 425669.4 ± 50.7 | 429629.4 ± 91.7 |
| Pre-dose C1D15 | 174658.7 ± 75.5 | 189047.7 ± 80.9 |
| Post-dose C1D15 | 456390.9 ± 70.6 | 547940.5 ± 60.2 |
| Pre-dose C1D22 | 185140.7 ± 78.0 | 286607.9 ± 25.7 |
| Post-dose C1D22 | 495612.5 ± 57.3 | 656862.8 ± 29.7 |
| Pre-dose C2D1 | 24903.4 ± 47.3 | 148097.2 ± 193.7 |
| Post-dose C2D1 | 474157.9 ± 108.0 | 415814.9 ± 106.3 |
| Pre-dose C3D1 | 34111.0 ± 164.7 | 25879.8 ± 572.2 |
| Pre-dose C4D1 | 19811.2 ± 218.1 | 30655.9 ± 128.9 |
| Pre-dose C5D1 | 27021.6 ± 152.0 | 35176.1 ± 84.1 |
| Pre-dose C6D1 | 28734.6 ± 116.9 | 30383.0 ± 88.8 |
| End of Treatment (week 24) | 12367.0 ± 349.9 | 33813.6 ± 61.9 |
| Follow-up visit (week 38) | 369.0 ± NA | — |
| End of Study (up to week 52) | 278.0 ± NA | — |
An AE was defined as any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. SAEs were defined as death, a life-threatening AE, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, a congenital anomaly or birth defect, or an important medical event that jeopardized participant and required medical intervention to prevent 1 of the outcomes listed in this definition. A summary of other non-serious AEs and all serious AEs, regardless of causality is located in Reported AE section.
| Participants | Cohort 1 (Newly Diagnosed or Relapsed Participants) | Cohort 2 (Refractory Participants) |
|---|---|---|
| Number of Participants With AEs During the Follow-up Period | 8 | 5 |
An AE was defined as any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. SAEs were defined as death, a life-threatening AE, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, a congenital anomaly or birth defect, or an important medical event that jeopardized participant and required medical intervention to prevent 1 of the outcomes listed in this definition. A summary of other non-serious AEs and all serious AEs, regardless of causality is located in Reported AE section.
| percentage of participants | Cohort 1 (Newly Diagnosed or Relapsed Participants) | Cohort 2 (Refractory Participants) |
|---|---|---|
| Percentage of Participants With AEs During the Follow-up Period | 44.4 | 38.5 |
Collected over Week 1 to Week 52 (Weeks 1-24 [Treatment Period]; Weeks 25-52 [Follow-up Period]). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cohort 1 (Newly Diagnosed or Relapsed Participants) Treatment Period (Weeks 1-24) | 0/18 (0%) | 2/18 (11.1%) | 15/18 (83.3%) |
| Cohort 2 (Refractory Participants) Treatment Period (Weeks 1-24) | 0/13 (0%) | 3/13 (23.1%) | 12/13 (92.3%) |
| Cohort 1 (Newly Diagnosed or Relapsed Participants) Follow-up Period (Weeks 25-52) | 0/18 (0%) | 1/18 (5.6%) | 8/18 (44.4%) |
| Cohort 2 (Refractory Participants) Follow-up Period (Weeks 25-52) | 0/13 (0%) | 1/13 (7.7%) | 5/13 (38.5%) |
| Event | Cohort 1 (Newly Diagnosed or Relapsed Participants) Treatment Period (Weeks 1-24) | Cohort 2 (Refractory Participants) Treatment Period (Weeks 1-24) | Cohort 1 (Newly Diagnosed or Relapsed Participants) Follow-up Period (Weeks 25-52) | Cohort 2 (Refractory Participants) Follow-up Period (Weeks 25-52) |
|---|---|---|---|---|
| Foot fractureInjury, poisoning and procedural complications | 0/18 | 1/13 | 0/18 | 0/13 |
| NeutropeniaBlood and lymphatic system disorders | 0/18 | 1/13 | 0/18 | 0/13 |
| Type I hypersensitivityImmune system disorders | 0/18 | 1/13 | 0/18 | 0/13 |
| GoutMetabolism and nutrition disorders | 0/18 | 0/13 | 0/18 | 1/13 |
| Infusion related reactionInjury, poisoning and procedural complications | 1/18 | 0/13 | 0/18 | 0/13 |
| Cerebrovascular accidentNervous system disorders | 0/18 | 0/13 | 1/18 | 0/13 |
| COVID-19Infections and infestations | 1/18 | 0/13 | 0/18 | 0/13 |
| Event | Cohort 1 (Newly Diagnosed or Relapsed Participants) Treatment Period (Weeks 1-24) | Cohort 2 (Refractory Participants) Treatment Period (Weeks 1-24) | Cohort 1 (Newly Diagnosed or Relapsed Participants) Follow-up Period (Weeks 25-52) | Cohort 2 (Refractory Participants) Follow-up Period (Weeks 25-52) |
|---|---|---|---|---|
| Infusion related reactionInjury, poisoning and procedural complications | 0/18 | 8/13 | 0/18 | 0/13 |
| HypogammaglobulinaemiaImmune system disorders | 7/18 | 1/13 | 1/18 | 0/13 |
| Oedema peripheralGeneral disorders | 2/18 | 4/13 | 0/18 | 1/13 |
| BronchitisInfections and infestations | 0/18 | 4/13 | 1/18 | 0/13 |
| NauseaGastrointestinal disorders | 4/18 | 1/13 | 0/18 | 0/13 |
| Lipase increasedInvestigations | 3/18 | 0/13 | 1/18 | 0/13 |
| HeadacheNervous system disorders | 3/18 | 0/13 | 0/18 | 0/13 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 3/18 | 0/13 | 1/18 | 0/13 |
| Chest painGeneral disorders | 1/18 | 2/13 | 1/18 | 0/13 |
| PyrexiaGeneral disorders | 0/18 | 2/13 | 0/18 | 0/13 |
The Full Analysis Set (FAS) included all participants who received at least one dose of study drug.
| Age, Continuous(years) | Cohort 1 (Newly Diagnosed or Relapsed Participants) | Cohort 2 (Refractory Participants) | Total |
|---|---|---|---|
| Mean | 59.2 ± 11.34 | 55.0 ± 12.47 | 57.5 ± 11.81 |
| Sex: Female, Male(Participants) | Cohort 1 (Newly Diagnosed or Relapsed Participants) | Cohort 2 (Refractory Participants) | Total |
|---|---|---|---|
| Female | 5 | 2 | 7 |
| Male | 13 | 11 | 24 |
| Ethnicity (NIH/OMB)(Participants) | Cohort 1 (Newly Diagnosed or Relapsed Participants) | Cohort 2 (Refractory Participants) | Total |
|---|---|---|---|
| Hispanic or Latino | 2 | 2 | 4 |
| Not Hispanic or Latino | 16 | 8 | 24 |
| Unknown or Not Reported | 0 | 3 | 3 |
| Race (NIH/OMB)(Participants) | Cohort 1 (Newly Diagnosed or Relapsed Participants) | Cohort 2 (Refractory Participants) | Total |
|---|---|---|---|
| American Indian or Alaska Native | 1 | 0 | 1 |
| Asian | 4 | 0 | 4 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 1 | 1 |
| White | 13 | 8 | 21 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 4 | 4 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — In accordance with Biogen's Clinical Trial Transparency and Data Sharing Policy on https://www.biogentrialtransparency.com/
Data sharing details ↗ · vivli.org
Ran from Oct 2019 to primary completion in Jan 2022, 27 months.
Results were first posted in Dec 2024, 2 years 11 months after primary completion. A results delay was requested in Nov 2022.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Felzartamab
Glomerulonephritis, Membranous →